The New Kids on the Block: Patient-Specific Considerations for SGLT2, GLP-1, and GIP/GLP-1

Saturday, March 25, 2023

2:30 PM – 3:30 PM

Location: Convention Center, Room 129AB

CPE Credit 1 Hours

Continuing Pharmacy Education (CPE) Credit

ACPE Number: 0202-0000-23-102-L01-P
Activity Type: Knowledge
Number of Hours: 1

Speaker(s)

Jenn Smith, PharmD, BCADM, CDCES, BCACP, FAPhA

Clinical Pharmacist Practitioner
Veterans Affairs
Anderson, South Carolina

Presentation PDF
Staci-Marie Norman, PharmD, CDCES, FAPhA (she/her/hers)

Pharmacist
Martin's Pharmacy
South Bend, Indiana

Disclosure(s):

Jenn Smith, PharmD, BCADM, CDCES, BCACP, FAPhA: No financial relationships to disclose

Staci-Marie Norman, PharmD, CDCES, FAPhA: No relevant disclosure to display

With increasing evidence supporting the use of SGLT2 inhibitors, GLP-1 receptor agonists and the newly approved GIP/GLP-1, the dynamic of diabetes pharmacotherapeutic management is changing. Attend this case-based discussion to review best practices for patient selection, titration and barriers to using these medications.

This activity is supported by an independent educational grant from Merck Sharp and Dohme Corp.

Learning Objectives:

Compare and contrast SGLT2 inhibitors, GLP-1 receptor agonists (GLP-1RAs) and GIP/GLP-1RAs in terms of A1C reduction, cardiovascular and renal benefit.
Explain potential barriers to use of SGLT2 inhibitors, GLP-1RAs and GIP/GLP-1RAs.
Given a patient's case, select the most appropriate treatment option for a patient with type 2 diabetes.